Patlis Alla 4

What Happened
Alla Patlis, Interim Chief Financial Officer & Controller of BrainStorm Cell Therapeutics, was granted 100,000 restricted stock units (RSUs) on February 26, 2026. The Form 4 reports the award as an acquisition (code A) at $0.00 per share (total $0). Per the filing, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six‑month anniversary, subject to continued employment.

Key Details

• Transaction date: 2026-02-26 (Form 4 filed 2026-05-29). The filing date is later than the transaction date (reporting delay).
• Transaction type/code: Award (A) — 100,000 RSUs; reported price $0.00; reported total $0.
• Vesting: 50% vest at grant; remaining 50% vests six months later, contingent on employment (per footnote).
• Shares owned after transaction: Not specified in this filing.
• No indication of a sale, exercise, 10b5-1 plan, or tax-withholding share surrender in this Form 4.

Context
RSUs are compensation that convert into shares upon vesting; because half vests at grant date, up to 50,000 units may have become shares immediately (subject to company procedures and tax withholding). Awards are a routine form of executive compensation and do not by themselves indicate buying or selling sentiment. The delayed filing is an administrative compliance note — insiders are generally required to report most transactions within two business days.